Radiology Center at Harding, a leading provider of top-quality medical imaging services to patients in Morris County and neighboring areas, has set up Hitachi's SOFIA 3D Whole Breast Ultrasound at its facilities. This innovative and highly efficient imaging technology is specially designed for the 40% of women of mammography age, who have dense breast tissue. The facility is available at the Radiology Center at Harding, for the first time ever in New Jersey.
While dense breasts are considered completely normal, they tend to hide cancer on a mammogram. In turn, this may reduce the ability of radiologists to find cancer, if present. For women with dense breasts, "negative," or "benign" mammogram does not reliably exclude cancer. In fact, the possibility of women with dense breasts having cancer detected soon after a "normal" or "negative" mammogram is very real. This is known as an "interval cancer" or cancer that’s detected between screening tests and professional exams.
Dense breasts and breast cancer: myth versus reality
Breast cancer is among the leading causes of cancer-related deaths in women – second only to lung cancer. But thanks to the advancement of diagnostic technologies, social innovation and timely medical intervention, death rates due to breast cancer have been on the decline.[1] One of the prominent factors in improving the chances of breast cancer survival is early detection. So far, mammography remains the only screening technique that has proved effective in diagnosing breast cancer time and again.[2] In addition, combining screening mammography with 3D whole breast ultrasound increases the ability to detect breast cancer from 78% to 92%.
However, may women put off the recommended mammography and ultrasound screening due to a combination of factors, including the lengthy exams, fear of pain and discomfort, unavailability of insurance cover, and so on. Lack of awareness about the availability and significance of advanced supplementary screening technologies, like ultrasound, is also a factor. A relatively painless, risk-free, efficient and less time-consuming technology that can be reimbursed by private health insurance players is the need of the hour.
Contrary to popular belief, breast density is not dependent on how a breast looks or feels, nor does the shape or size of the breast play any role in determining whether it is dense. A radiologist can only determine the breast density by examining the images from a mammogram. Dense breasts are identified in a mammogram when breasts show more dense tissue than fatty tissue. Dense tissue appears as white area on a mammogram, instead of transparent and dark, and this makes it difficult to see through. This white area can mask the appearance of cancer, hampering accurate diagnosis.
Having dense breasts puts women at higher risk for breast cancer. Breast density is a well-established predictor of breast cancer risk, exceeding family history. Mammography is known to miss every other cancer in dense breasts, so additional screening is often recommended. In fact, because breast density poses additional risks, state governments (36 states as of 2019) have passed legislation that requires providers to inform women of their breast density status and discuss what it means and what supplemental imaging options are available that can help detect breast cancer, earlier. Studies have shown that supplemental ultrasound exams in women with dense breasts can increase the number of cancers detected by 55%.
Life-saving technology
Hitachi's SOFIA 3D Whole Breast Ultrasound offers highly accurate breast ultrasound examination to women of all ages – particularly those with dense breasts. It eliminates the discomfort that women experience during breast screening, by way of being a more private and relatively pain-free experience. With an ergonomic design, the Hitachi SOFIA 3D Whole Breast Ultrasound scan is done with the patient lying in a prone position, with her bodyweight causing breast compression naturally. In addition to the ergonomics, Hitachi SOFIA 3D Whole Breast Ultrasound offers superior experience and usability in multiple ways:[3]
- Scans at the rate of 30 seconds per breast, which reduces time taken drastically
- Seamless experience for technicians through touch-screens and fully automated scans on button-press
- Doubles as a scan bed for other diagnostic ultrasound exams
- Needs no lengthy pre-scan preparation or additional consumables
Hitachi SOFIA’s cutting-edge imaging technology utilizes ultrasound to scan the entire breast, while the patient lies in a comfortable prone position. There is no painful breast compression or radiation associated with this procedure. The scan produces 3D volumetric images of the breast for review by the radiologist.
Radiology Center at Harding
With a tradition of excellence in diagnostic imaging, Harding Radiology Center combines over 35 years of experience of its radiologists with the latest advances in the field of medical imaging. It functions with the mission of providing quality diagnostic imaging services in a soothing, comfortable environment. With an ACR accredited facility utilizing the latest technology and equipment, it remains on the cutting edge of diagnostic imaging techniques, offering patients and doctors tools that make quicker and more accurate diagnoses as a cost-effective alternative to surgical procedures.
The center’s state-of-the-art Radiology Information System and Picture Archiving Communications system (RIS/PACS) is the industry gold standard for digital archiving of all patient information and imaging. The full range of diagnostic imaging services include Open MRI, Computed Tomography (CT), 3D Mammography & 3D Automated Breast Ultrasound, Digital X-ray, DEXA and Ultrasound.
The center remains steadfast in its commitment to the health and wellness of its communities. This is especially true for diseases like cancer, where early detection and preventive screening can really make a difference. Hence, for women over the age of 50, those who have a family history of cancer, and who have dense breasts, the center recommends they consult their healthcare provider and discuss additional screening options.
To book an appointment, call: 908-221-0603
1201 Mount Kemble Avenue, Morristown, NJ 07960
www.hardingradiology.com
[1] https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html
[2] https://www.who.int/cancer/detection/breastcancer/en/
[3] https://social-innovation.hitachi/en-us/solutions/life_economy/sofia-3d
Technological advancements in radiotherapy and the rising incidence of cancer are the major factors driving the growth of radiotherapy market.
Additionally, the growing adoption of radiotherapy procedures for cancer treatment, increasing use of particle therapy for cancer treatment, and the rising number of conferences and symposia focusing on the advancements in radiotherapy are some of the other major factors driving the growth of this market.The global radiotherapy market is projected to reach USD 6.8 billion by 2023 from USD 5.6 billion in 2018, at a CAGR of 4.1%Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=567 Radiotherapy Market Insights by Application:Based on application, the external beam radiotherapy market is segmented into prostate cancer, breast cancer, lung cancer, head & neck cancer, colorectal cancer, and other cancers.
The prostate cancer segment is expected to account for the second-largest share of the radiotherapy market in 2018.
The growing incidence of prostate cancer and the high success rates and minimal long-term risks achieved with external beam radiotherapy are the major factors driving the growth of this market segment.Radiotherapy Market Analysis by Type: Based on type, the external beam radiotherapy market is classified into IGRT, IMRT, stereotactic therapy, particle beam therapy, and 3D-CRT.
The particle beam therapy segment is expected to witness the highest CAGR during the forecast period.
Advancements in the field of particle beam therapy (such as PBS) and increasing research activities in the field of radiation oncology using proton therapy systems are the key factors driving the growth of this segment.Key Players In Global Radiotherapy Devices Market:The major players operating in the radiotherapy market are Varian Medical Systems, Inc. (US), Elekta (Sweden), Accuray Incorporated (US), Ion Beam Applications SA (Belgium), ViewRay, Inc. (US), IsoRay Medical, Inc. (US), Hitachi Ltd. (Japan), Panacea Medical Technologies Pvt.
The global teleradiology market size is estimated to reach USD 11.5 billion by 2026 registering a CAGR of 18.4%, according to a new report by Grand View Research, Inc.
Rising prevalence of chronic diseases, such as osteoporosis and arthritis, along with growing geriatric population are expected to drive the market.
According to the WHO, 9.6% of men and 18% of women are suffering from various forms of arthritis, globally.
Over 82% of people suffering from osteoarthritis have difficulty in movement and around 25% are not able to perform daily activities.In addition, legislative amendments made by various governments worldwide for diagnostic imaging services will enhance the growth of this market during the forecast period.
This has allowed better access to diagnostic imaging for various conditions.
North America was the major regional market in 2018 and accounted for 39.45% of the global share due to factors, such as higher amount of funding for R, patient awareness levels, and cancer prevalence.The region is likely to expand further on account of favorable government initiatives for improving the healthcare facilities in rural areas and increased healthcare expenditure in this region are contributing to the market growth.
According to the new market research report by MarketsandMarkets, [128 Pages Report] the global vascular closure devices market is expected to reach USD 984.6 Million by 2022 from USD 704.8 Million in 2017, at a CAGR of 6.9%.The large number of approvals for vascular closure devices, the high prevalence of cardiovascular diseases, high prevalance of obesity, and increasing focus of market players on large-bore vascular closure devices.The report provides an overall understanding of the market.
The geographic segments included in this report are North America, Europe, Asia-Pacific, and the Rest of the World (RoW).Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180101468The Passive Approximators segment to grow at the highest CAGR during the forecast periodOn the basis of type, the global vascular closure device market is segmented into passive approximators, active approximators, and external hemostatic devices.
The passive approximators consist of a plug, sealant, or a gel that can be deployed at the arteriotomy site to passively close the femoral artery.
The key factors propelling the growth of the the vascular closure devices market are the rising prevalence of cardiovascular diseases, increase in obese population, increasing number of regulatory approvals, and increasing focus of market players on large-bore vascular closure devices.The increasing interventional procedures using radial access, the high cost of vascular closure devices, and the risks associated with vascular closure devices are the major restraints for the marketVascular closure devices are relatively high-priced devices compared to manual compression devices.
The cost of VCDs essentially adds up to the patient’s hospitalization bill and even increases the per patient cost for hospitals and simultaneously reduces profits.Moreover, radial artery access makes it more convenient for doctors to achieve hemostasis using simple manual compression methods.
Interventional procedures using radial artery access do not generally require vascular closure devices, which is another factor that leads to cost savings.Additionally, malfunctioning of devices, poor quality, and underperformance of devices are the primary causes of product recalls.
